Clinical Characteristics and Antimicrobial Susceptibility Trends in *Citrobacter* Bacteremia: An 11-Year Single-Center Experience

Raeseok Lee 1, Su-Mi Choi 1, Sung Jin Jo 2, Jehoon Lee 3, Sung-Yeon Cho 1,4, Si-Hyun Kim 1, Dong-Gun Lee 1,4, and Hyeong-Seok Jeong 4

1Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea
2Department of Laboratory Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea
3Vaccine Bio Research Institute, Seoul, College of Medicine, The Catholic University of Korea, Seoul, Korea
4Emergency care center, Konyang University Hospital, Daejeon, Korea

ABSTRACT

**Background:** Recently, *Citrobacter freundii* bacteremia outbreak in a neonatal intensive care unit has attracted public attention in Korea. However, *Citrobacter* bacteremia is uncommon and usually occurs in patients with underlying diseases such as malignancy and hepatobiliary diseases. Increase in resistance and emerging of multidrug resistance among *Citrobacter* species have gradually been reported. The aim of this study was to investigate the clinical characteristics and outcome of *C. freundii* and non-*freundii* bacteremia and antimicrobial susceptibility trends.

**Materials and Methods:** We reviewed the medical records of patients with *Citrobacter* bacteremia at St. Mary’s Hospital, from 2007 to 2017.

**Results:** A total of 43 patients with a median age of 72 (24-93) years was identified and 90.7% of them had comorbidities. Twenty-nine (67.4%) patients had *C. freundii* bacteremia while 14 had non-*freundii* bacteremia (six of *C. braakii*, five of *C. koseri*, two of *C. amalonaticus* and one of *C. youngae*). A total of 26 (51.2%) patients had community-acquired infection and intra-abdominal infection including hepatobiliary tract was the most common portal of entry (24/43, 55.8%). Moreover, hepatobiliary tract was the leading primary site of nosocomial infection (9/17, 52.9%). Polymicrobial bacteremia was observed in 21 (48.8%) patients. The percentages of *Citrobacter* species susceptible to ampicillin, amikacin, aztreonam, cefazolin, cefoxitin, cefotaxime, cefepime, piperacillin-tazobactam, ciprofloxacin, and imipenem were 9.5%, 97.6%, 73.8%, 9.5%, 14.3%, 71.4%, 92.9%, 83.3%, 83.3% and 100%, respectively. The resistance rate did not increase during the study period. Of 39 patients treated with antibiotics, 36 (92.3%) received appropriate empirical antibiotics. Overall mortality was 18.6%. High Charlson comorbidity index and Pitt bacteremia score were significant risk factors for death in univariate analysis and showed trends in the multivariate analysis. No significant difference in clinical features and antimicrobial susceptibility rate was observed between *C. freundii* and non-*freundii* bacteremia.

**Conclusion:** *Citrobacter* bacteremia was predominant in the elderly with comorbidities, while no pediatric case was observed. Hepatobiliary tract is the leading primary focus of bacteremia both in community-acquired and nosocomial infection. The rate of susceptibility to antibiotics has not changed in the last 11 years.

**Keywords:** Bacteremia; *Citrobacter freundii*; Drug resistance; Prognosis
INTRODUCTION

Citrobacter species, which are facultative anaerobic Gram-negative bacilli, exist all around us. However, Citrobacter infection is uncommon; they account for 0.8% of all Gram-negative infections and 3%–6% of all isolates of Enterobacteriaceae in nosocomial infection [1-3]. Furthermore, Citrobacter bacteremia is made up of only a few cases of the whole Citrobacter infection [4]. Citrobacter bacteremia usually occurs in adult patients with underlying diseases such as malignancy and intra-abdominal diseases [4-7].

Although, the risk of Citrobacter infection in neonates and immunocompromised patients has been gaining attention [8-10], Citrobacter infection is still out of the keen interest. Furthermore, its clinical significance, mortality, and resistance to antibiotics were not accurately evaluated because it was considered to have low virulence [11], low incidence, and to occur only in patients with comorbidities. Recently, the outbreak of Citrobacter freundii bacteremia in a neonatal intensive care unit has attracted public attention in Korea [12].

This study aimed to investigate the clinical characteristics and prognostic factors of Citrobacter bacteremia and compare them with those of C. freundii and non-freundii bacteremia. We also aimed to evaluate the antibiotic susceptibility patterns and trends.

MATERIALS AND METHODS

1. Study patients

We retrospectively reviewed the medical records of patients with Citrobacter bacteremia between January 2007 and December 2017, at Yeouido St. Mary’s hospital, a 450-bed (700-bed before in 2015) university-affiliated hospital. Demographic and clinical characteristics such as age, sex, underlying diseases, primary site of infection, severity of infection, treatment measures and outcome of the enrolled patients and microbiologic data such as identification of Citrobacter spp. and susceptibility to the antimicrobial agents of Citrobacter were obtained. There was one patient who had recurrent episodes of C. freundii bacteremia which were apart more than 16 months and showed different antibiogram between the two isolates. This study was approved by the institutional review board of the Yeouido St. Mary’s hospital (no. SC18RESI0115) and informed consent was waived because of the retrospective design of the study.

2. Bacterial isolation and identification

Blood culture was performed using the BD BACTEC™ FX blood culture system (Becton Dickinson, MA, USA). Bacterial identification and antimicrobial susceptibility tests were performed using the Vitrek 2 system (bioMérieux, Marcy L’Etoile, France) following the manufacturer’s recommendation. Result of the susceptibility test was interpreted based on the Clinical and Laboratory Standards Institute guidelines (CLSI) [13-15], and all results were interpreted in accordance with the changed CLSI guidelines. Intermediate susceptibility was defined being resistant.

3. Definitions

Citrobacter bacteremia was defined as detection of an organism isolated from at least one bottle of blood culture with presence of clinical symptoms and signs of infection [5, 6, 16]. Nosocomial infection was defined as showing a positive result of blood culture obtained
48 hours after admission and presence of symptoms and signs of infection or transferred patients from another hospital with infection [5, 6, 17]. The primary site of infection was determined based on the clinical features and that was consistent with the laboratory, radiologic and other culture results [5, 6]. Polymicrobial infection was defined as simultaneous isolation of more than one microorganism from blood culture in which *Citrobacter* was identified [5, 16]. Antimicrobial therapy, provided 3 months prior to admission was considered as recent antibiotic exposure. Appropriateness of empirical antibiotics was defined as the administration of at least one antimicrobial agent, to which *Citrobacter* was sensitive *in vitro*, with dosage appropriate for end organ function [5, 6]. Overall mortality included in-hospital death and hopeless discharge. There was one hopeless discharge who gave up further treatment in a very unstable vital sign. Patients who refused treatment or were immediately transferred to another hospital were excluded from the prognostic factor analysis.

4. **Statistical analysis**

Categorical variables were analyzed using the χ²-test or Fisher’s exact test. Student’s *t*-test for parametric methods for Charlson comorbidity index or Mann-Whitney test for non-parametric methods were performed for other continuous variables. Multivariate logistic regression was performed to define the risk factors for death using all significant variables with a *P*-value of less than 0.1 in the univariate analysis and known risk factors in previous studies [4-7]. A backward selection process was used. Multicollinearity was verified using variance inflation factors. A two-sided *P*-value of less than 0.05 was considered significant. All statistical analyses were performed using SPSS software 21 (SPSS Inc., Chicago, IL, USA).

**RESULTS**

1. **Clinical characteristics of the patients**

From January 2007 through December 2017, 43 episodes of *Citrobacter* bacteremia were identified and annual incidence was presented in Figure 1. There was no clustering of cases, which were suspected as outbreak during the study period. The median age was 72 years with a range of 24–93. No pediatric case was observed. Twenty-nine (67.4%) cases had bacteremia caused by *C. freundii* and 14 had non-∗freundii* bacteremia (six of *C. braakii*, five of *C. koseri*, two of *C. amalonaticus* and one of *C. youngae*). A total of 39 (90.7%) patients had comorbidities. Hepatobiliary and pancreatic diseases including malignancy were the most common underlying diseases (Table 1). The median age of four patients without underlying diseases was 28.5 years (range of 24-61). Three of four patients, had *Citrobacter* bacteremia that originated from appendicitis and one was unknown.

The intra-abdominal infection (32/43, 74.4%) including the hepatobiliary tract, urinary tract, and gastrointestinal tract was the most common portal of entry. Hepatobiliary tract was the leading primary site both in community-acquired and nosocomial infections (38.5% and 52.9%, respectively). Twenty-one (48.8%) patients had polymicrobial bacteremia, which consisted of eight isolates of *Klebsiella* spp., seven of *Enterococcus* spp., three of *Escherichia coli*, two of *Pseudomonas* spp., two of *Streptococcus* spp., two of *Enterobacter* spp., one of *Staphylococcus aureus*, and one of *Actinomyces odontolyticus*. A total of 26 (60.5%) patients had community-acquired infection and 10 (23.3%) had recent antibiotic exposure. In 17 (39.5%) patients with nosocomial infections, the hepatobiliary tract (9/17, 52.9%) was the most common site of infection, followed by the central line-associated blood stream infection (4/17, 23.5%) and a case of urinary tract infection, skin and soft tissue infection, gastrointestinal tract...
Characteristics of *Citrobacter* bacteremia

### Table 1. Clinical characteristics and outcome of the patients with *Citrobacter* bacteremia

| Number of patients (%) | Total (N = 43) | freudii (N = 29) | non-freudii (N = 14) | P       |
|------------------------|----------------|-----------------|---------------------|---------|
| Age, year, median (IQR) | 72 (60.0–78.5) | 72 (58.0–78.0) | 72 (64.0–81.0)      | 0.351   |
| Sex, Male              | 32 (74.4)      | 23 (79.3)       | 9 (64.3)            | 0.493   |
| Underlying conditions  |                |                 |                     |         |
| Hepatobiliary & pancreatic diseases a | 14 (32.6) | 8 (27.6) | 6 (42.9) | 0.513 |
| Solid cancer           | 6 (14.0)       | 5 (17.2)        | 1 (7.1)             | 0.670   |
| Hematologic malignancy | 3 (7.0)        | 3 (10.3)        | 0 (0.0)             | 0.012   |
| Cardiovascular diseases| 10 (23.3)      | 3 (10.3)        | 7 (50.0)            | 0.012   |
| COPD                   | 2 (4.7)        | 0 (0.0)         | 2 (14.3)            | 0.190   |
| Diabetes Mellitus      | 13 (30.2)      | 8 (27.6)        | 5 (35.7)            | 0.850   |
| Chronic kidney disease | 7 (16.3)       | 6 (20.7)        | 1 (7.1)             | 0.492   |
| Chronic liver diseases | 2 (4.7)        | 2 (6.9)         | 0 (0.0)             | 0.815   |
| Charlson comorbidity index, mean ± SD | 5.5 ± 3.1 | 5.1 ± 3.4 | 6.4 ± 2.3 | 0.227   |
| Pitt bacteremia score, median (IQR) | 0.0 (0.0–2.0) | 0.0 (0.0–2.0) | 0.5 (0.0–3.0) | 0.492   |
| Primary site of infection |                  |                 |                     | 0.091   |
| Hepato-biliary tract   | 19 (44.2)      | 12 (41.4)       | 7 (50.0)            |         |
| Urinary tract          | 8 (18.6)       | 5 (17.2)        | 3 (21.4)            |         |
| Gastrointestinal tract | 5 (11.6)       | 5 (17.2)        | 0 (0.0)             |         |
| Central venous catheter| 4 (9.3)        | 4 (13.8)        | 0 (0.0)             |         |
| Skin and soft tissue   | 2 (4.7)        | 0 (0.0)         | 2 (14.3)            |         |
| Respiratory tract      | 1 (2.3)        | 0 (0.0)         | 1 (7.1)             |         |
| Unknown                | 4 (9.3)        | 3 (21.4)        | 1 (7.1)             |         |
| Polymicrobial bacteremia| 21 (48.8) | 15 (51.7) | 6 (42.9) | 0.826 |
| Nosocomial infection   | 17 (39.5)      | 13 (44.8)       | 4 (28.6)            | 0.491   |
| Device associated infection | 8 (18.6) | 8 (27.5) | 0 (0.0) | 0.078 |
| Urinary catheter       | 3 (10.3)       | 3 (10.3)        | 0 (0.0)             |         |
| Central venous catheter| 4 (13.8)       | 4 (13.8)        | 0 (0.0)             |         |
| Internal biliary stent | 1 (3.4)        | 1 (3.4)         | 0 (0.0)             |         |
| Previous exposure of antibiotics | 10 (23.3) | 8 (27.6) | 2 (14.3) | 0.560 |
| Invasive drainage procedures | 9 (20.9) | 6 (20.7) | 3 (21.4) | 1.000 |
| No. of patients treated with antibiotics | 39 (90.6) | 26 (89.7) | 13 (92.9) | 1.000 |
| Appropriate initial antibiotics | 36 (92.3) | 25 (96.1) | 11 (84.6) | 0.846 |
| Time interval between bacteremia and appropriate antibiotics, days, median (IQR) | 0.0 (0.0–0.0) | 0.0 (0.0–0.0) | 0.0 (0.0–2.0) | 0.057 |
| Duration of antibiotics, days, median (IQR) | 15 (10.5–25.0) | 14 (11.0–27.0) | 17 (9.0–24.0) | 0.905 |
| Duration of hospitalization, days, median (IQR) | 12 (5.5–37.0) | 12 (7.0–40.0) | 14 (5.0–26.0) | 0.938 |

IQR, inter-quartile range; COPD, chronic obstructive pulmonary disease; SD, standard deviation.

*Includes benign and malignant diseases such as cholangitis and pancreatitis and cancer.*

Figure 1. Annual incidence of *Citrobacter* bacteremia from 2006 to 2017.

https://icjournal.org

https://doi.org/10.3947/ic.2019.51.1.1
infection, and primary bacteremia, respectively. No significant difference in clinical features was observed between *C. freundii* and non-*freundii* bacteremia. The detailed characteristics are presented in Table 1.

2. Treatment outcome and risk factors for death

Of 43 episodes, 39 (90.6%) were treated with antibiotics. Four patients were not treated because they were transferred to other hospitals or refused treatment because their underlying diseases were already at terminal stage. Out of 39 patients treated with antibiotics, 36 (92.3%) received appropriate initial antibiotics, which consisted of third-generation cephalosporins (22/39, 56.4%, such as cefoperazone-sulbactam, ceftriaxone, and ceftazidime), piperacillin-tazobactam (9/39, 23.1%), quinolones (3/39, 7.7%), carbapenems (2/39, 5.1%), ampicillin-sulbactam (2/39, 5.1%), and cefuroxime (1/39, 2.5%). Among three patients who did not receive appropriate empirical antibiotics (two isolates showed resistance to third-generation cephalosporins and one showed resistance to piperacillin-tazobactam), two patients received appropriate antibiotics within a week after the result of the susceptibility test was obtained. The time interval between blood culture and administration of appropriate antibiotics tended to be longer in the non-*freundii* group (mean day, 0.46 days in the *freundii* group vs 3.23 days in the non-*freundii* group, \( P = 0.057 \)). Furthermore, the duration of antibiotics use and length of hospitalization were longer in the non-*freundii* group, but were not significant (Table 1). Nine (20.9%) patients were inserted with the following drainages; pig-tail catheter for ascites in five patients, percutaneous transhepatic biliary drainage (PTBD) or percutaneous transhepatic gallbladder drainage in four patients, and internal biliary stent in one patient. One patient was inserted with a pig-tail catheter for ascites and PTBD at the same time.

Overall mortality was (8/43, 18.6%) and was not significantly different between patients with *freundii* bacteremia and those with non-*freundii* bacteremia (4/29, 13.8% vs. 4/14, 28.6%, \( P = 0.454 \)). In univariate analysis, Charlson comorbidity index, Pitt bacteremia score and undergoing invasive drainage procedures were significant predictors of patients’ outcome (Table 2). The multivariate analysis did not show any independent risk factors for mortality. However, Charlson comorbidity index, Pitt bacteremia score, and undergoing invasive drainage only showed trends to be related to death (Table 2).

3. Antimicrobial susceptibilities

Antimicrobial susceptibility data were available in 42 blood isolates, and rate of antimicrobial susceptibility are presented in Table 3. Comparing the first 6 years (from 2007 to 2012) and the last 5 years (from 2013 to 2017), no change was observed in the rate of resistance to the

---

**Table 2. Risk factors for mortality in patients with Citrobacter bacteremia**

| Characteristic                  | Univariate analysis         | Multivariate analysis          |
|--------------------------------|-----------------------------|--------------------------------|
|                                | Odds ratio | CI (95%) | \( P \)        | Odds ratio | CI (95%) | \( P \) |
| Age (age <75 years vs. ≥75 years) | 0.300 | 0.032–2.849 | 0.294 | 1.944 | 0.923–4.093 | 0.080 |
| Charlson comorbidity index     | 1.596 | 1.075–2.369 | 0.020 |                   |
| Nosocomial acquisition         | 9.583 | 1.002–91.621 | 0.050 |                   |
| Primary site of infection:     | 79.420 | –5.591–12.200 | 0.342 | 3.725 | 0.910–15.247 | 0.067 |
| Polymicrobial bacteremia       | 49.254 | –1.777–13.753 | 0.312 | 3.725 | 0.910–15.247 | 0.067 |
| Pitt bacteremia score          | 1.903 | 1.508–3.421 | 0.032 | 3.725 | 0.910–15.247 | 0.067 |
| Appropriate initial antibiotics | 0.188 | 0.024–1.485 | 0.13  | 3.725 | 0.910–15.247 | 0.067 |
| Invasive drainage              | 38.750 | 3.564–421.301 | 0.003 | 28.008 | 0.787–997.115 | 0.067 |

CI, confidence interval; vs., versus.
tested antibiotics. Additionally, no significant difference in antimicrobial susceptibilities was observed between *C. freundii* and non-*freundii* (data not shown). Compared with community-acquired infection, *Citrobacter* spp. isolated from patients with nosocomial infection had decreased susceptibility to ceftazidime (22/25, 88.0% vs. 8/17, 47.1%; *P* = 0.011) and aztreonam (22/25, 88.0% vs. 9/17, 52.9%; *P* = 0.029). All isolates were susceptible to carbapenems.

**DISCUSSION**

We analyzed the clinical characteristics, treatment outcome and antibiotic susceptibility rates of 43 patients with *Citrobacter* bacteremia at a single institute in Korea. No significant difference in clinical features and antimicrobial susceptibility rate was observed between *C. freundii* and non-*freundii* bacteremia. Since previous studies on *Citrobacter* bacteremia in Korean people had been conducted more than 15 years ago [5], our data could show recent trends. No pediatric case was observed, and there was no clustering of cases. Although the incidence of *Citrobacter* bacteremia appears to be high in 2014, compared to other years, species and the patterns of antimicrobial susceptibility of the isolates were diverse. We could not find any epidemiologic relations. Majority of patients were elderly people with a median age of 72 years, which was 15 years older than the average age of 55.6 years reported in the previous domestic study by Kim *et al.* [5]. More than 90% of the enrolled patients had at least one or more comorbidities, which was similar to those reported in previous studies [4, 6, 18, 19]. However, *Citrobacter* bacteremia could occur in young and healthy patients, even in neonates [8]. In our study, four patients without underlying diseases had a median age of 28.5 years, and all of them survived. Several studies reported that *Citrobacter* bacteremia primarily occurs in the urinary tract [4, 7, 18, 20]. By contrast, hepatobiliary tract was the most common primary site of community-acquired and nosocomial infections in our study as other reports [5, 6, 21, 22]. Polymicrobial infection accounted for almost half of *Citrobacter* bacteremia cases, which was relatively high, compared with 35.2% in previous study by Kim *et al.* [5]. The most possible reason is that *Citrobacter* bacteremia is mostly derived from intra-abdominal infection. Therefore, we should consider the possibility of co-infection with *Enterobacteriaceae* and *Enterococcus* spp. and choice empirical antibiotics. Unlike previous studies, in which nosocomial infection was predominant (77%–94.6%) [5, 7, 18, 23], community-acquired infection (60.5%) was dominant in our study. Our hospital was changed from a tertiary

| Table 3. Antimicrobial susceptibility rates of *Citrobacter* isolates |
|---------------------------------|
| **Number of patients (%)** | **2007–2012 (N = 18)** | **2013–2017 (N = 24)** | **Total (N = 42)** | **P** |
|-------------------------------|-----------------|-----------------|-----------------|-----|
| Amikacin                     | 18 (100.0)     | 23 (95.8)       | 41 (97.6)       | 1.000|
| Amoxicillin/clavulanic acid  | 4 (22.2)       | 3 (12.5)        | 7 (16.7)        | 0.676|
| Ampicillin                   | 1 (5.6)        | 3 (12.5)        | 4 (9.5)         | 0.820|
| Aztreonam                    | 11 (61.1)      | 20 (83.3)       | 31 (73.8)       | 0.205|
| Cefazolin                    | 2 (11.1)       | 2 (8.3)         | 4 (9.5)         | 1.000|
| Cefepime                     | 17 (94.4)      | 22 (91.7)       | 39 (92.9)       | 1.000|
| Cefotaxime                   | 12 (66.7)      | 18 (75.0)       | 30 (71.4)       | 0.805|
| Cefoxitin                    | 4 (22.2)       | 2 (8.3)         | 6 (14.3)        | 0.408|
| Cefazidime                   | 10 (55.6)      | 20 (83.3)       | 30 (71.4)       | 0.104|
| Ciprofloxacin                | 14 (77.8)      | 21 (87.5)       | 35 (83.3)       | 0.676|
| Gentamicin                   | 15 (83.3)      | 23 (95.8)       | 38 (90.5)       | 0.404|
| Imipenem                     | 18 (100.0)     | 24 (100.0)      | 42 (100.0)      | NA   |
| Piperacillin-tazobactam      | 14 (77.8)      | 21 (87.5)       | 35 (83.3)       | 0.676|
| Trimethoprim-sulfamethoxazole| 13 (72.2)      | 22 (91.7)       | 35 (83.3)       | 0.209|

*Intermediate susceptibility was considered as resistance.*
hospital to a secondary hospital in 2015, which is thought to have contributed to this finding. Because tertiary hospitals receive patients from primary and secondary hospitals in Korea, nosocomial infections are likely to be more common. Knowing whether Citrobacter bacteremia is caused by community-acquired infection or nosocomial infection is important in choosing appropriate empirical antibiotics. Although nosocomial acquisition does not affect the mortality rate, it could affect antimicrobial susceptibility rates. We presented that the rate of resistance to ceftazidime and aztreonam was significantly higher in isolates from nosocomial infections than in community-acquired infections.

The mortality of Citrobacter bacteremia was reported to be between 16.6–48.3% [5, 7, 21]. Polymicrobial infection is known to increase mortality and length of hospital stay among adults. In addition, stay in the intensive care unit, nosocomial infection, and sources of bacteremia other than the urinary tract are also considered as risk factors for death [5, 7, 24]. We showed that Charlson comorbidity index and Pitt bacteremia score were associated with the overall mortality. Therefore, the underlying conditions and severity of initial presenting symptoms and signs are the most important determinants of outcome. Although Charlson comorbidity index was possible factor for mortality, we could not find any statistical significance in individual underlying diseases such as metastatic malignancy or diabetes with complications. Undergoing invasive drainage procedure was a significant risk factor for death in the univariate analysis but not in the multivariate analysis, which was different from that reported in previous studies [5, 6]. One possible reason is that six out of nine patients underwent the drainage procedure with the disease progressing considerably. Another reason is that five patients had an insertion of pigtail catheter as palliative treatment and not as an active therapeutic procedure.

Increasing resistance to extended spectrum cephalosporins in Citrobacter spp. has been reported [4, 5, 25–27]. Moreover, there is a consensus that Citrobacter isolates have become increasingly drug-resistant even for aminoglycosides and quinolones [28, 29]. However, we could not find an increase in the rate of resistance to the 15 examined antimicrobial agents (100% susceptible to ertapenem, data not shown) between the first 6 years (from 2007 to 2012) and the later 5 years (from 2013 to 2017). There has been another concern that susceptibility patterns differed substantially between C. freundii and non-freundii isolates. However, there was no significant difference in susceptibility rate between C. freundii and non-freundii isolates. Although it was lower than the previously reported data in Korea [5], the rate of resistance to second- and third-generation cephalosporins in our study was considerable; the rates of resistance to cefoxitin, cefotaxime, and ceftazidime were 85.7%, 28.6%, and 28.6%, respectively. On the contrary, carbapenems, cefepime, and amikacin were still promising against Citrobacter spp. To the best of our knowledge, the susceptibility rate of Citrobacter spp. to carbanem is between 97% and 100% [4, 5], although carbapenem-resistant Citrobacter infection is emerging [30]. It accounted for 1.9% of all carbapenemase producing Enterobacteriaceae reported in Korea in 2016 [31]. Thus, more attention should be paid to infection with multidrug-resistant Citrobacter spp.

This study showed the different clinical characteristics and antibiotic susceptibility rate of Citrobacter spp. between medical institutions even in the same city and country. This is the most recent clinical study in Korea, and it can serve as a basis when treating patients with Citrobacter bacteremia. Because the data in this study are limited due to the small number of patients in a single institute and retrospective study design, a multicenter study with a large sample size is ongoing.
In conclusion, *Citrobacter* bacteremia is predominant in the elderly with comorbidities. Hepatobiliary tract is the leading primary focus of bacteremia both in community-acquired and nosocomial infections. The clinical features of *Citrobacter* bacteremia were not different between *C. freundii* and non-*freundii* bacteremia. The rate of susceptibility to antibiotics has not changed during the last 11 years. Isolates that cause nosocomial infections are more resistant to third-generation cephalosporin and aztreonam. Co-morbidity and severity of initial manifestations are critical for outcome.

REFERENCES

1. Lavigne JP, Defez C, Bouziges N, Mahamat A, Sotto A. Clinical and molecular epidemiology of multidrug-resistant *Citrobacter* spp. infections in a French university hospital. Eur J Clin Microbiol Infect Dis 2007;26:439-41. [PUBMED] [CROSSREF]
2. Lipsky BA, Hook EW 3rd, Smith AA, Plorde JJ. *Citrobacter* infections in humans: experience at the Seattle Veterans Administration Medical Center and a review of the literature. Rev Infect Dis 1980;2:746-60. [PUBMED] [CROSSREF]
3. Jones RN, Jenkins SG, Hoban DJ, Pfaffer MA, Ramphal R. In vitro efficacy of six cephalosporins tested against *Enterobacteriaceae* isolated at 38 North American medical centres participating in the SENTRY Antimicrobial Surveillance Program, 1997/1998. Int J Antimicrob Agents 2000;15:111-8. [PUBMED] [CROSSREF]
4. Samonis G, Karageorgopoulos DE, Kofteridis DP, Matthaiou DK, Sidiropoulou V, Maraki S, Falagas ME. *Citrobacter* infections in a general hospital: characteristics and outcomes. Eur J Clin Microbiol Infect Dis 2009;28:61-8. [PUBMED] [CROSSREF]
5. Kim BN, Woo JH, Ryu J, Kim YS. Resistance to extended-spectrum cephalosporins and mortality in patients with *Citrobacter freundii* bacteremia. Infection 2003;31:202-7. [PUBMED]
6. Shih CC, Chen YC, Chang SC, Luh KT, Hsieh WC. Bacteremia due to *Citrobacter* species: significance of primary intraabdominal infection. Clin Infect Dis 1996;23:543-9. [PUBMED] [CROSSREF]
7. Drelichman V, Band JD. Bacteremias due to *Citrobacter diversus* and *Citrobacter freundii*. Incidence, risk factors, and clinical outcome. Arch Intern Med 1985;145:1808-10. [PUBMED] [CROSSREF]
8. Doran TI. The role of *Citrobacter* in clinical disease of children: review. Clin Infect Dis 1999;28:384-94. [PUBMED] [CROSSREF]
9. Hawkley T, Chang D, Pollard W, Ferraro D. Ecthyma gangrenosum caused by *Citrobacter freundii*. BMJ Case Rep 2017;pii: bcr-2017-220996. [PUBMED]
10. Lai CC, Tan CK, Lin SH, Liu WL, Liao CH, Huang YT, Hsueh PR. Bacteraemia caused by non-*freundii*, non-*koseri* *Citrobacter* species in Taiwan. J Hosp Infect 2010;76:332-5. [PUBMED] [CROSSREF]
11. Pepperell C, Kus JV, Gardam MA, Humar A, Burrows LL. Low-virulence *Citrobacter* species encode resistance to multiple antimicrobials. Antimicrob Agents Chemother 2002;46:3555-60. [PUBMED] [CROSSREF]
12. Korea Centers for Disease Control and Prevention (KCDC). Update on epidemiological investigation of infant deaths at Ewha Womans University Mokdong Hospital NICU. Available at: http://www.cdc.go.kr/CDC/eng/info/CdcKPPress.jsp?menuslds=HOME002-MNU0576MNU0586&fid=8652&q_type=&q_value=&ecid=77357&pageNum. Accessed 7 July 2018.
13. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; 27th ed. CLSI document M100. Wayne, PA: CLSI; 2017.
14. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; Twenty-fourth informational supplement. CLSI document M100-S24. Wayne, PA: CLSI; 2014.
15. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; twentieth informational supplement. CLSI document M100-S20. Wayne, PA: CLSI; 2010.
16. Sutter D, Stagliano D, Braun L, Williams F, Arnold J, Ottolini M, Epstein J. Polymicrobial bloodstream infection in pediatric patients: risk factors, microbiology, and antimicrobial management. Pediatr Infect Dis J 2008;27:400-5. [PUBMED] [CROSSREF]

17. Lenz R, Leal JR, Church DL, Gregson DB, Ross T, Laupland KB. The distinct category of healthcare associated bloodstream infections. BMC Infect Dis 2012;12:85. [PUBMED] [CROSSREF]

18. Mohanty S, Singhal R, Sood S, Dhawan B, Kapil A, Das BK. Citrobacter infections in a tertiary care hospital in Northern India. J Infect 2007;54:58-64. [PUBMED] [CROSSREF]

19. Brenner DJ, O’Hara CM, Grimont PA, Janda JM, Falsen E, Aldova E, Ageron E, Schindler J, Abbott SL, Steigerwalt AG. Biochemical identification of Citrobacter species defined by DNA hybridization and description of Citrobacter gillenii sp. nov. (formerly Citrobacter genomospecies 10) and Citrobacter marliniae sp. nov. (formerly Citrobacter genomospecies 11). J Clin Microbiol 1999;37:2619-24. [PUBMED]

20. Samonis G, Anaissie E, Elting L, Bodey GP. Review of Citrobacter bacteremia in cancer patients over a sixteen-year period. Eur J Clin Microbiol Infect Dis 1991;10:479-85. [PUBMED] [CROSSREF]

21. Liu LH, Wang NY, Wu AY, Lin CC, Lee CM, Liu CP. Citrobacter freundii bacteremia: Risk factors of mortality and prevalence of resistance genes. J Microbiol Immunol Infect 2018;51:565-72. [PUBMED] [CROSSREF]

22. Lew PD, Baker AS, Kunz LJ, Moellering RC Jr. Intra-abdominal Citrobacter infections: association with biliary or upper gastrointestinal source. Surgery 1984;95:398-403. [PUBMED]

23. Jones SR, Ragsdale AR, Kutscher E, Sanford JP. Clinical and bacteriologic observations on a recently recognized species of enterobacteriaceae, Citrobacter diversus. J Infect Dis 1973;128:563-5. [PUBMED] [CROSSREF]

24. McKenzie FE. Case mortality in polymicrobial bloodstream infections. J Clin Epidemiol 2006;59:760-1. [PUBMED] [CROSSREF]

25. Liu LH, Wang NY, Wu AY, Lin CC, Lee CM, Liu CP. Citrobacter freundii bacteremia: Risk factors of mortality and prevalence of resistance genes. J Microbiol Immunol Infect 2018;51:565-72. [PUBMED] [CROSSREF]

26. Kanamori H, Yano H, Hirakata Y, Endo S, Arai K, Ogawa M, Shimojima M, Aoyagi T, Hatta M, Yamada M, Nishimaki K, Kitagawa M, Kunishima H, Kaku M. High prevalence of extended-spectrum β-lactamases and qnr determinants in Citrobacter species from Japan: dissemination of CTX-M-2. J Antimicrob Chemother 2011;66:2255-62. [PUBMED] [CROSSREF]

27. Zhang R, Yang L, Cai JC, Zhou HW, Chen GX. High-level carbapenem resistance in a Citrobacter freundii clinical isolate is due to a combination of KPC-2 production and decreased porin expression. J Med Microbiol 2008;57:332-7. [PUBMED] [CROSSREF]

28. Orrett FA, Shurland SM. Prevalence of bacterial pathogens and susceptibility patterns from clinical sources in Trinidad. West Indian Med J 2000;49:205-9. [PUBMED]

29. Wang JT, Chang SC, Chen YC, Luh KT. Comparison of antimicrobial susceptibility of Citrobacter freundii isolates in two different time periods. J Microbiol Immunol Infect 2000;33:258-62. [PUBMED]

30. Venditti C, Fortini D, Villa L, Vulcano A, D’Arezzo S, Capone A, Petrosillo N, Nisi C, Carattoli A, Di Caro A. Circulation of blaKPC-3-Carrying IncX3 Plasmids among Citrobacter freundii Isolates in an Italian Hospital. Antimicrob Agents Chemother 2017;61:pii:e0050-17. [PUBMED] [CROSSREF]

31. Park JW, Lee E, Lee SL, HM L. Status of carbapenemase producing Enterobacteriaceae incidence in Korea, 2015-2016. Public Health Wkly Rep 2017;10:1243-7.